"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
Descriptor ID |
D007004
|
MeSH Number(s) |
D27.505.696.422
|
Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2001 | 2 | 1 | 3 |
2002 | 2 | 1 | 3 |
2004 | 2 | 2 | 4 |
2005 | 3 | 2 | 5 |
2006 | 3 | 2 | 5 |
2007 | 3 | 2 | 5 |
2008 | 2 | 4 | 6 |
2009 | 5 | 3 | 8 |
2010 | 3 | 3 | 6 |
2011 | 2 | 4 | 6 |
2012 | 3 | 2 | 5 |
2013 | 3 | 0 | 3 |
2014 | 9 | 4 | 13 |
2015 | 8 | 2 | 10 |
2016 | 7 | 0 | 7 |
2017 | 1 | 3 | 4 |
2018 | 1 | 2 | 3 |
2019 | 3 | 3 | 6 |
2020 | 2 | 5 | 7 |
2021 | 1 | 4 | 5 |
2022 | 1 | 4 | 5 |
2023 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Davidson MB. In adults with BMI =27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk. Ann Intern Med. 2023 11; 176(11):JC129.
-
Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 08 05; 402(10400):472-483.
-
Lopez-Candales A, Monte S, Sawalha K, Norgard NB. Time to revisit the true role of metformin in type 2 diabetes mellitus. Postgrad Med. 2023 08; 135(6):539-542.
-
Yedjou CG, Grigsby J, Mbemi A, Nelson D, Mildort B, Latinwo L, Tchounwou PB. The Management of Diabetes Mellitus Using Medicinal Plants and Vitamins. Int J Mol Sci. 2023 May 22; 24(10).
-
Nyakundi BB, Yang J. Uses of Papaya Leaf and Seaweed Supplementations for Controlling Glucose Homeostasis in Diabetes. Int J Mol Sci. 2023 Apr 06; 24(7).
-
Lopez-Candales A, Sawalha K, Drees BM, Norgard NB. In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients. Postgrad Med. 2023 05; 135(4):323-326.
-
Thompson CA, St?rmer T. Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts. Diabetes Care. 2023 02 01; 46(2):249-251.
-
Frias JP, Lee ML, Carter MM, Ebel ER, Lai RH, Rikse L, Washington ME, Sonnenburg JL, Damman CJ. A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab. 2023 05; 25(5):1203-1212.
-
Davidson MB. A simplified straightforward protocol for the use of U-500 regular insulin. Diabetes Obes Metab. 2023 02; 25(2):634-636.
-
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ. 2022 10 03; 379:e070717.